CILON-T Late Breaking Trial : Randomized prospective trial of dual vs. triple antiplatelet therapy after DES implantation ACC & i2 summit, March 15th 2010, Atlanta, Georgia Hyo-Soo Kim, MD, PhD Seoul National University Hospital Seoul, Korea Seoul National University Hospital Nothing to disclose Seoul National University Hospital CILON-T trial CILostazol-based triple anti-platelet therapy ON Ischemic Complication after drug-eluting stenT implantation Multicenter, prospective, randomized trial PROBE (Prospective Randomized Open-label Blinded Evaluation) Principal investigator Hyo-Soo Kim, MD, PhD Clinical trials identifier NCT00776828 Seoul National University Hospital CILON-T trial : participating centers Centers Investigators Seoul National University Hospital Hyo-Soo Kim, MD, PhD Seoul National University Bundang Hospital In-Ho Chae, MD, PhD Konyang University Hospital Jang-Ho Bae, MD, PhD Korea University Guro Hospital Seung-Woon Rha, MD, PhD Chungbuk University Hospital Myeong-Chan Cho, MD, PhD Seoul National University Hospital Background of the CILON-T trial I. Accumulating evidences suggest the relationship between clopidogrel resistance & clinical events. II. Recent studies reported the value of using VerifyNow (PRU) in predicting clinical events. III. Efficacy of adding cilostazol in reducing clinical events has been reported in the registry or small randomized controlled study of specific subpopulation. Seoul National University Hospital Background of the CILON-T trial Efficacy of adding cilostazol on DAT in reducing clinical events or PRU value has not been tested • in the real-world all-comer patients with DES implantation • at the level of large randomized controlled study. Seoul National University Hospital Assessed for eligibility (n=976) Randomization (n=960) TAT (n=477) Atorvastatin (n=241) Rosuvastatin (n=236) DAT (n=483) Atorvastatin (n=242) 3 Withdrawal at patient request 14 Withdrawal at clinician’s judgment 3 Failed PCI TAT (n=457) 2 Withdrawal at patient request 19 Withdrawal at clinician’s judgment 4 Failed PCI DAT (n=458) 915 patients with successful PCI & follow-up at 6 month - Cardiovascular death, nonfatal MI, ischemic stroke, TLR - Platelet (P2Y12) reaction unit Rosuvastatin (n=241) CILON-T Trial Endpoints Primary Endpoint Composite of clinical outcomes within six months (cardiac death, MI, ischemic stroke & TLR) Secondary endpoint PRU level measured at discharge & 6 mo after the index procedure All cause of death, stent thrombosis, and each component of primary endpoint at six months Safety Endpoint Bleeding complications according to TIMI criteria The incidence of drug discontinuation Heart rate Seoul National University Hospital Key participation criteria Inclusion criteria Age 18~80yrs All-comers : patients with native de-novo coronary artery lesions for which DES implantation was feasible Exclusion criteria Hepatic dysfunction (GOT/GPT >*3 UNL) Renal dysfunction (Scr>2.0mg/dl or on dialysis) LV dysfunction (EF <30%) Uncontrolled hematological disease Patients taking warfarin or other anti-platelet agents Allergy to study medications Seoul National University Hospital RESULTS Seoul National University Hospital Clinical profiles of patients TAT (n=457) DAT (n=458) p 62.8±9.6 62.8±9.2 0.999 Men 321 (68.6%) 326 (68.3%) 0.935 Hypertension 291 (64.5%) 305 (66.9%) 0.454 Diabetes mellitus 160 (35.5%) 147 (32.2%) 0.303 Diet 24 (5.3%) 17 (3.7%) OHA 103 (22.8%) 116 (25.4%) 33 (7.3%) 14 (3.1%) 107 (23.7%) 122 (26.8%) 0.470 Previous PCI 29 (6.4%) 39 (8.6%) 0.225 Previous CABG 8 (1.8%) 13 (2.7%) 0.281 Age, yrs Insulin Current smoker Clinical diagnosis 0.748 Stable angina 168 (41.3%) 153 (37.1%) Unstable angina 174 (42.8%) 196 (47.6%) Acute myocardial infarction 42 (10.3%) 42 (10.2%) 8 (1.9%) 5 (1.2%) Total cholesterol 176.1±39.4 177.4±4.31 LDL cholesterol 104.7±34.6 107.9±40.2 Silent ischemia 0.62 Seoul National University Hospital 0.20 Profiles of Medication at Discharge TAT (n=457) DAT (n=458) Pvalue Aspirin 99.8 (449) 99.8 (451) 0.997 Statin 98.9 (451) 100 (451) 0.259 Beta-blocker 52.9 (239) 51.6 (232) 0.691 ACE inhibitor or ARB 37.6 (169) 45.8 (207) 0.012 Calcium channel blocker 26.0 (117) 27.2 (123) 0.680 Nitrates 42.7 (187) 42.7 (193) 0.728 2.7 (12) 2.0 (9) 0.488 Medication at discharge Proton pump inhibitor Seoul National University Hospital Angiographic profiles of patients TAT (n=457) DAT (n=458) Lesion locations LAD LCx RCA Left main ACC-AHA lesion classification A B1 B2 C Ostial lesions Calcified lesions Bifurcation lesion Thrombus on angiography 220 (48.4%) 91 (20.2%) 105 (23.1%) 23 (5.1%) 222 (49.3%) 107 (23.5%) 124 (27.6%) 13 (2.9%) p 0.166 0.633 12 (2.8%) 126 (29.7%) 55 (13.0%) 231 (54.5%) 112 (24.5%) 105 (24.1%) 145 (31.7%) 34 (7.8%) 10 (2.3%) 126 (29.1%) 46 (10.6%) 251 (58.0%) 109 (23.8%) 128 (29.3%) 132 (28.8%) 38 (8.7%) 0.802 0.092 0.556 0.637 Seoul National University Hospital Procedural profiles of patients TAT (n=457) DAT (n=458) P Lesion length, mm 21.1±13.4 22.2±13.9 0.244 MLD, mm 0.75±0.49 0.79±0.50 0.246 Reference vessel diameter, mm 2.96±0.52 2.93±0.52 0.416 No. of stent / lesion 1.23±0.51 1.18±0.44 0.164 Post-procedural MLD, mm 2.29±0.51 2.23±0.51 0.107 Type of stents 0.102 Paclitaxel-eluting (TAXUS) 228 (49.9%) 225(49.1%) Zotarolimus-eluting (Endeavor) 194 (42.5%) 207 (45.2%) 156 (34.1%) 163 (35.6%) Multi-lesion intervention 0.64 Seoul National University Hospital Results: P2Y12 reaction unit (PRU): TAT vs DAT PRU 340 p < 0.001 p < 0.001 TAT DAT 300 260 220 255.7 232.1 180 206.6 210.7 140 100 At discharge After 6 months Seoul National University Hospital Results: Change of PRU for 6 months : TAT vs DAT P2Y12 reaction unit (PRU) TAT DAT p < 0.001 p =0.23 At discharge 6 mo At discharge 6 mo Seoul National University Hospital Results: Clinical outcomes depending on PRU value Composite of CD, nonfatal MI, ischemic stroke & TLR Composite of CD, nonfatal MI & ischemic stroke TLR p=0.077 p=0.486 p=0.037 Seoul National University Hospital Results: Clinical outcomes depending on anti-plt regimen TAT (n=457) DAT (n=458) p 39 (8.5%) 42 (9.2%) 0.73 4 (0.9%) 6 (1.3%) 0.75 0 3 (0.7%) 0.25 Nonfatal MI 4 (0.9%) 3 (0.7%) 0.73 Ischemic stroke 5 (1.1%) 4 (0.9%) 0.75 TLR 30 (6.6%) 32(7.2%) 0.79 Stent thrombosis 3 (0.7%) 5 (1.1%) 0.73 Death, nonfatal MI, ischemic stroke 13 (2.8%) 13 (2.8%) 1.0 CD, nonfatal MI, ischemic stroke 9 (2.0%) 10 (2.0%) 1.0 Primary endpoint CD, nonfatal MI, ischemic stroke and TLR Secondary endpoint Death from any cause Cardiac death Seoul National University Hospital Results: Clinical outcomes depending on anti-plt regimen Triple anti-PLT regimen Double anti-PLT regimen Composite of CD, nonfatal MI & ischemic stroke Composite of CD, nonfatal MI, ischemic stroke & TLR TLR p=0.818 for log-rank test p=0.742 for log-rank test p=0.701 for log-rank test 9.2% 7.2% 8.5% 6.6% 2.0% 2.0% DAT 458 452 450 425 416 DAT 458 452 451 449 447 DAT 458 458 449 426 418 TAT 457 450 449 428 418 TAT 457 452 452 451 448 TAT 457 450 449 429 421 Seoul National University Hospital Distribution of PRU in pts with MACCE Seoul National University Hospital PRU value versus Anti-PLT regimen to predict MACCE Composite of CD, nonfatal MI, ischemic stroke & TLR Composite of CD, nonfatal MI & ischemic stroke TLR Seoul National University Hospital Subgroup analysis : TAT vs DAT Baseline characteristics HR 95% CI 0.78 1.02 0.37-1.60 1.34 0.64 0.69-2.58 0.32-1.29 0.66 3.41 0.39-1.13 1.12-10.4 Lesion length ≥ 28mm <28mm 0.79 0.70 0.34-1.84 0.38-1.31 Reference vessel diameter <2.75mm ≥2.75mm 0.80 0.85 0.38-1.69 0.45-1.60 Diabetes Yes No Age ≥ 65 yr <65 yr Sex Male Female 0 TAT better 1 0.57-1.83 2 DAT better Seoul National University Hospital Results: Safety outcomes : TAT vs DAT Variable TAT (n=457) DAT (n=458) Bleeding complications P 0.511 Major 2 (0.4%) 1 (0.2%) Minor 1 (0.2%) 0 (0%) 30 (6.6%) 3 (0.7%) <0.001 Baseline 69.7±11.9 69.2±12.7 0.62 6 months 73.3±12.0 68.4±13.7, <0.001 Drug discontinuation Heart rate, /min Seoul National University Hospital Results: Independent predictors for MACCE (Cox-regression analysis) Risk factor Unadjusted HR (95% CI) Adjusted HR (95% CI) 1.75 (1.07~2.86) 1.90 (1.05~3.43) 1.42 (1.04~1.93) 1.63 (1.12~2.37) Use of cilostazol 0.91 (0.59~1.41) 0.88 (0.50~1.56) Diabetes mellitus 1.22 (0.78~1.91) 1.53 (0.86~2.73) Lesion length ≥28mm (vs. <28mm) High PRU level (every increase of tertile) Female 0.65 (0.39~1.10) 0.64 (0.33~1.24) Hypertension 1.31 (0.81~2.13) 1.29 (0.67~2.52) Age 1.02 (0.99~1.04) 1.01 (0.97~1.04) Diagnosis of AMI 0.62 (0.25~1.53) 1.01 (0.36~2.86) Seoul National University Hospital Study limitations Open-label study, but with blinded evaluation Platelet reactivity measured by single method Not powered to verify the effect of cilostazol on the hard endpoint, such as CD, nonfatal MI or stent thrombosis Seoul National University Hospital Summary of CILON-T randomized controlled trial TAT achieved lower PPR (post-treatment platelet reactivity) than DAT. But it did not necessarily reduce MACCE within six months after DES implantation, because there were substantial numbers of hypo-responders even to TAT. The importance of PPR is reflected by the finding that the patients with low PPR (PRU < 210 unit) did not develop any thrombotic event (CD, MI, or ischemic stroke) irrespective of anti-platelet regimen. Seoul National University Hospital Conclusion of CILON-T randomized controlled trial Tailored decision on the adjunctive use of cilostazol according to PPR (post-treatment platelet reactivity) may be important to reduce clinical events in patients with DES implantation. Seoul National University Hospital